Abstract 2091P
Background
Nurses provide information and care on cancer treatment side effects prevention and management. Skin toxicities are common side effects and can be associated with treatment dose reduction or discontinuation. Minimizing skin side effects and using photoprotection improve patient outcomes and quality of life.
Methods
The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) teamed to create consensus recommendations about using dermocosmetics in cancer patients. They assembled a group of international experts from nursing and other disciplines who manage cancer patients. After literature review, the group held a consensus meeting to give guidance on the use of dermocosmetics with oncology treatments.
Results
Dermocosmetics (or cosmeceuticals) are products with therapeutic value in addition to cosmetic. They contain ingredients that can help repair and support the skin barrier by hydrating the skin, maintaining a healthy microbiome. For general recommendations the group agreed: * Start skin care at the same time as cancer interventions known to be associated with skin toxicities, with a goal of preventing and minimizing problems. * Hydration of the skin relieves symptoms and reduces exacerbations of xerosis. * Use cleansers with pH close to 5 and avoid basic or neutral pH cleansers. * Photoprotection should be part of initial recommendations for all Consensus recommendations for the use of dermocosmetics in specific skin toxicities management were also made.
Conclusions
Nurses have an essential role in educating patients about skin care as part of their holistic approach to patient care. This new consensus focuses on the practical and beneficial impact of dermocosmetics to avoid and manage side effects as well as prevent dryness, irritation, and sensitivity. Patient education can help prevent high-grade toxicities and reduce healthcare costs by allowing patients to have an active role in their treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
La Roche Posay.
Disclosure
P. Dielenseger, M. Lacouture, K. Khosrotehrani, G. De Barros Silva, J. Ryan Wolf, E.O. Atenguena, B. Dreno: Financial Interests, Personal and Institutional, Advisory Role: La Roche Posay. D. Kerob: Financial Interests, Personal, Full or part-time Employment: La Roche Posay. All other authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06